India Unbranded Generics Plans An Industry Threat As Elections Loom?
As national elections loom, India’s prime minister has said the government will expand a retail scheme to sell cut-price no-name generic drugs intended to make medicines more affordable for the poor, and some analysts are expecting a potentially significant commercial impact on the country's main branded generics sector.
You may also be interested in...
In an unprecedented move, eight of India’s top pharma companies, including Sun Pharma, Cipla, Torrent and Lupin, have set up a common vehicle for digitization initiatives. Having acquired local market research firm AIOCD AWACS and B2B platform Pharmarack, could the mandate extend to other services?
India's cut-price generic drugs scheme appears to have gathered some pace, covering over 700 medicines, offering sharp price differentials over brand name therapies and also garnering some private sector interest. But its on-ground impact in improving affordable access to medicines is still limited, some experts claim.
India has outlined a set of initiatives to revive its thus far "unsatisfactory" "Jan Aushadhi" cut-price generic medicines scheme, including a distribution effort beyond the exclusive stores for these products and potentially even offering online purchases and home delivery.